Targeting specific proteins to improve treatment for acute myeloid leukemia.
Official title: Role of targeting ATPases BRG1/BRM in therapy of AML
Funded at University of Tx Md Anderson Can Ctr · NIH-11126207 · Data updated 2026-11-12
This study is looking at how certain proteins, called BRG1 and BRM, can be targeted to create new treatments for people with acute myeloid leukemia (AML), especially those with specific genetic changes, to help improve their chances of recovery while protecting healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 11, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $542,663 |
| NIH project number | 1R01CA291918-01A1 |
| Project ID | NIH-11126207 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute myeloid leukemia, especially those with MLL rearrangements or NPM1 mutations.
✕Less likely to help
Patients with other types of leukemia or those who do not have the specific genetic mutations targeted by this research may not benefit.
What this research studies
This research investigates the role of ATPases BRG1 and BRM in the treatment of acute myeloid leukemia (AML). It focuses on developing new targeted therapies that can effectively treat AML patients, particularly those with specific genetic mutations. The approach involves using novel agents that inhibit these proteins, which are crucial for the survival of AML cells, while sparing normal cells. By conducting preclinical studies, the research aims to identify effective treatment combinations that could lead to better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with acute myeloid leukemia, potentially improving survival rates and reducing relapse.
How similar studies have gone: Other research has shown promising results with similar targeted approaches in treating acute myeloid leukemia, indicating potential for success in this area.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Fiskus, Warren Campbell — University of Tx Md Anderson Can Ctr
- Study coordinator: Fiskus, Warren Campbell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.